TABLE 2. Reported syncopal events* per 100,000 persons vaccinated and patient demographic characteristics after receipt of Janssen COVID-19 vaccine and influenza vaccine — Vaccine Adverse Events Reporting System, United States, July 1, 2019–April 12, 2021.
| Characteristic | Vaccine, no. (%) |
|
|---|---|---|
| Janssen COVID-19 | Influenza | |
| Reporting date |
Mar–Apr 2021 |
Jul 2019–Jun 2020 |
| No. of syncope cases* |
653 |
60 |
| Doses administered |
7,980,000 |
124,000,000 |
| Rate† |
8.2 |
0.05 |
|
Sex
| ||
| Female |
327 (50) |
28 (47) |
| Male |
325 (50) |
32 (53) |
| Missing |
1 (0) |
0 (—) |
|
Age group, yrs
| ||
| Median (range) |
30 (18–82) |
26 (18–88) |
| 18–29 |
311 (48) |
36 (60) |
| 30–39 |
164 (25) |
12 (20) |
| 40–49 |
77 (12) |
4 (7) |
| 49–59 |
68 (10) |
3 (5) |
| ≥60 |
26 (4) |
5 (8) |
| Missing | 7 (1) | 0 (0) |
* CDC reviewed reports to the Vaccine Adverse Events Reporting System that contained the Medical Dictionary for Regulatory Activities preferred terms “syncope” or “syncope vasovagal” for all Janssen COVID-19 vaccines administered during March 2–April 12, 2021, and any influenza vaccine administered to an adult aged ≥18 years during July 1, 2019–June 30, 2020. Events that occurred off-site or ≥1 hour after vaccine administration and those in persons who received diphenhydramine or epinephrine at the vaccination visit were not included.
† Cases per 100,000 persons vaccinated.